SynthesisInternational journal of molecular sciences2017
Target Therapies for Uterine Carcinosarcomas: Current Evidence and Future Perspectives.
Synthesis in International journal of molecular sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 3 syntheses or guidelines pooled it, 37 citations in OpenAlex.
- The clinical characteristics and treatment of ovarian malignant mesoderm mixed tumor: a systematic review.Journal of ovarian research · 2022Pooled it
- Uterine manipulator in total laparoscopic hysterectomy: safety and usefulness.Updates in surgery · 2020Pooled it
- Laparoscopic management of uncommon benign uterine tumors: a systematic review.Updates in surgery · 2019Pooled it
- Feasibility IB trial of paclitaxel/carboplatin + Galunisertib. (a small molecule inhibitor of the kinase domain of type 1 TGF-B receptor) in patients with newly diagnosed, persistent or recurrent carcinosarcoma of the uterus or ovary.Gynecologic oncology · 2025Article
- Odontogenic carcinosarcoma: a comprehensive review of clinical and therapeutic insights.Frontiers in oral health · 2025Review
- Case report: Carcinosarcoma of uterus in nulliparous women.Frontiers in oncology · 2024Article
- Insights into Clinical Features and Outcomes of Adrenal Cortical Carcinosarcoma.Diagnostics (Basel, Switzerland) · 2022Article
- Identification of Ferroptosis-Related Gene Prognostic Signature and HSF1 for Reversing Doxorubicin and Gemcitabine Resistance in Uterine Carcinosarcoma.Disease markers · 2022Article
- Nomogram to predict overall survival based on the log odds of positive lymph nodes for patients with endometrial carcinosarcoma after surgery.BMC cancer · 2021Article
- Lenvatinib plus pembrolizumab in patients with advanced or recurrent uterine carcinosarcoma.Gynecologic oncology reports · 2021Article
- Carcinosarcomas of the Uterus: Prognostic Factors and Impact of Adjuvant Treatment.Cancer management and research · 2021Article
- Article
- Net survival of patients with colorectal cancer: a comparison of two periods.Updates in surgery · 2019Article
- Shedding light on the EpCAM: An overview.Journal of cellular physiology · 2019Review
- Outcome of adjuvant radiotherapy after total hysterectomy in patients with uterine leiomyosarcoma or carcinosarcoma: a SEER-based study.BMC cancer · 2019Article
- The association between childbirth, breastfeeding, and uterine fibroids: an observational study.Scientific reports · 2019Observational
- Article
- Liquid biopsy for lung cancer immunotherapy.Oncology letters · 2019Review
- MiR-214 Regulates the Human Hair Follicle Stem Cell Proliferation and Differentiation by Targeting EZH2 and Wnt/β-Catenin Signaling WayTissue engineering and regenerative medicine · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carcinosarcomas (CS) in gynecology are very infrequent and represent only 2-5% of uterine cancers. Despite surgical cytoreduction and subsequent chemotherapy being the primary treatment for uterine CS, the overall five-year survival rate is 30 ± 9% and recurrence is extremely common (50-80%). Due to the poor prognosis of CS, new strategies have been developed in the last few decades, targeting known dysfunctional molecular pathways for immunotherapy. In this paper, we aimed to gather the available evidence on the latest therapies for the treatment of CS. We performed a systematic review using the terms "uterine carcinosarcoma", "uterine Malignant Mixed Müllerian Tumors", "target therapies", "angiogenesis therapy", "cancer stem cell therapy", "prognostic biomarker", and "novel antibody-drug". Based on our results, the differential expression and accessibility of epithelial cell adhesion molecule-1 on metastatic/chemotherapy-resistant CS cells in comparison to normal tissues and Human Epidermal Growth Factor Receptor 2 (HER2) open up new possibilities in the field of target therapy. Nevertheless, future investigations are needed to clarify the impact of these new therapies on survival rate and medium-/long-term outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.